Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are an essential part of the treatment of respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). In Burundi, the market for bronchodilator drugs has been developing steadily in recent years, driven by several factors.
Customer preferences: In Burundi, the demand for bronchodilator drugs is mainly driven by the increasing prevalence of respiratory diseases. The population's preference for self-medication and the availability of over-the-counter (OTC) bronchodilator drugs have also contributed to the growth of the market. However, the lack of awareness among the population about the proper use of these drugs and the potential side effects remains a challenge.
Trends in the market: The Burundian market for bronchodilator drugs is expected to continue to grow in the coming years, driven by the increasing prevalence of respiratory diseases and the government's efforts to improve access to healthcare services. The market is also expected to benefit from the growing trend towards generic drugs, which are more affordable than branded drugs.
Local special circumstances: Burundi is a low-income country with a weak health system, which poses significant challenges for the development of the bronchodilator drugs market. The lack of adequate healthcare infrastructure and the shortage of healthcare professionals limit the availability of these drugs in rural areas. Moreover, the high poverty rate in the country makes it difficult for many people to afford the cost of these drugs, which can be a barrier to access.
Underlying macroeconomic factors: The Burundian economy has been growing at a slow pace in recent years, with limited opportunities for investment and job creation. This has limited the purchasing power of the population, which has a direct impact on the demand for bronchodilator drugs. The government's efforts to improve the business environment and attract foreign investment could help to boost economic growth and increase the population's purchasing power, which would benefit the bronchodilator drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
